武田中国总裁单国洪离职，近期多家跨国药企在华高管变动

Group 1: Leadership Changes - Takeda China's President, Dan Guohong, will leave the company, with his last working day on June 30, 2023 [2] - Takeda China Vice President, Liu Yan, will temporarily take over the role of President [2] - Dan Guohong has served as Takeda China's President for 8 years, leading the company to become the third-largest market for Takeda globally [2] Group 2: Company Performance and Strategy - Under Dan Guohong's leadership, over half of Takeda China's business came from growth pipelines and newly launched products [2] - Takeda China has committed to launching 15 innovative drugs in China by 2025 as part of its "Wu Ju Future" five-year plan [2] - Takeda has been in the Chinese market for over 30 years, establishing a comprehensive pharmaceutical value chain [2] Group 3: Industry Context - The Chinese pharmaceutical market is undergoing significant changes due to policies like centralized drug procurement and negotiations for the medical insurance drug list [4] - Other multinational pharmaceutical companies, such as Merck, are also experiencing leadership changes in response to market dynamics [4] - Merck's China revenue for 2024 is projected to be $5.394 billion, a 20% decline year-on-year, attributed to decreased sales of its HPV vaccine [5]